No, CRISPR gene enhancing expertise isn’t going to “treatment” coronary heart illness. However a New York Times story by Gina Kolata on a particularly early research in animals prominently performs up simply this extraordinarily unlikely declare.
The Instances story is predicated on a press release issued by Verve Therapeutics, a brand new biotechnology firm based by Sekar Kathiresan, an influential heart specialist and genomic researcher related to the Broad Institute, Massachusetts Normal Hospital, and Harvard. Kathiresan and colleagues used a novel CRISPR base enhancing approach to knock out both the PCSK9 or ANGPTL3 genes in 14 monkeys. They reported that LDL and triglyceride ranges dropped dramatically two weeks after receiving the novel remedy.
The Instances headline raises quick considerations:
“Treatment”? “Succeeds”?
Click here to read the rest of the post on CVCT CardioBrief…
